Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 8/20 | 0.59 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | CAMKK2 | Q96RR4 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.42 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 2/20 | 0.39 |
| ▸ | INSR | P06213 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488654 | 0.90 | MAP4K1 (0.73) | MAP4K1ABL1CAMKK2CYP3A4AAK1 | |
| SCHEMBL12342946 | 0.89 | MAP4K1 (0.59) | MAP4K1ABL1CAMKK2CYP3A4AAK1 | |
| SCHEMBL12343173 | 0.88 | MAP4K1 (0.60) | MAP4K1ABL1CAMKK2CYP3A4AAK1 | |
| SCHEMBL3489122 | 0.86 | MAP4K1 (0.56) | MAP4K1ABL1CAMKK2CYP3A4AAK1 | |
| SCHEMBL3488848 | 0.86 | MAP4K1 (0.56) | MAP4K1ABL1CAMKK2CYP3A4AAK1 | |
| SCHEMBL12343600 | 0.85 | MAP4K1 (0.57) | MAP4K1ABL1CAMKK2CYP3A4AAK1 | |
| SCHEMBL12343291 | 0.85 | ABL1 (0.59) | MAP4K1ABL1CAMKK2CYP3A4AAK1 | |
| SCHEMBL3562909 | 0.85 | MAP4K1 (0.82) | MAP4K1ABL1CAMKK2CYP3A4AAK1 | |
| SCHEMBL12343602 | 0.84 | MAP4K1 (0.54) | MAP4K1ABL1CAMKK2CYP3A4AAK1 | |
| SCHEMBL12343141 | 0.84 | ABL1 (0.53) | MAP4K1ABL1CAMKK2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| EP-2134179-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7626021-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, TTK, MAP3K19 | MAP4K1 19/4885ABL1 141/4885CAMKK2 107/4885 |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | MAP3K20, TTK, MAP3K19 | MAP4K1 19/4885ABL1 141/4885CAMKK2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.